Eli Lilly and Prevail Therapeutics Inc. have announced a definitive agreement for Lilly to acquire Prevail for $1.040 billion. Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition will establish a new modality for drug discovery and development at Lilly, extending Lilly’s research efforts through the…
